Normocain (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride, the active ingredient in Normocain, is a local anesthetic (amide type) presented as a dental solution for infiltration and perineural use. It provides local anesthesia for dental procedures in adult patients.

GNH USA supplies Normocain as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Normocain is a local anesthetic used in dental practice to achieve reversible nerve block.

Dental procedures: provides local anesthesia for routine restorative work, extractions and endodontic therapy. Infiltration anesthesia: enables numbing of targeted oral tissues for minor surgeries. Perineural anesthesia: allows nerve block for oral surgery procedures.

Adverse reactions may occur following administration of Normocain.

Common Side Effects: - Transient tingling or numbness at the injection site - Mild swelling or bruising around the area - Temporary metallic taste in the mouth - Mild headache - Dizziness or light‑headedness - Localized itching or rash

Serious or Rare Side Effects: - Allergic reaction including anaphylaxis - Cardiovascular toxicity such as arrhythmia or hypertension - Methemoglobinemia (rare) - Seizures (rare) - Severe tissue necrosis at injection site - Persistent paresthesia lasting weeks to months

Before using Normocain, clinicians should consider several safety measures.

Allergy assessment: verify no known hypersensitivity to amide‑type anesthetics. Cardiovascular status: use caution in patients with uncontrolled hypertension. Pregnancy: avoid unless the benefit outweighs the potential risk. Drug interactions: assess concomitant use of other epinephrine‑containing products. Dosage control: limit total articaine dose per treatment session. Store at room temperature: keep in original container, protect from light and moisture.

Normocain may interact with other medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Beta‑blockers: may potentiate epinephrine‑induced tachycardia. - Monoamine oxidase inhibitors (MAOIs): increase risk of hypertensive crisis with epinephrine. - Tricyclic antidepressants: may enhance cardiovascular effects.

Moderate Interactions (Monitor Closely): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding risk. - Anticoagulants (e.g., warfarin): monitor for prolonged bleeding. - Other local anesthetics: avoid cumulative toxicity.